<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093972</url>
  </required_header>
  <id_info>
    <org_study_id>8507-014</org_study_id>
    <secondary_id>MK-8507-014</secondary_id>
    <nct_id>NCT05093972</nct_id>
  </id_info>
  <brief_title>MK-8507 in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)</brief_title>
  <official_title>An Open-Label, Single-Dose Clinical Study to Evaluate Pharmacokinetics of MK-8507 in Participants With Mild or Moderate Hepatic Impairment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacokinetics (PK) and safety of a single oral&#xD;
      dose of MK-8507 in participants with mild or moderate hepatic impairment (HI). It is&#xD;
      hypothesized that the area under the plasma concentration-time curve from dosing to&#xD;
      (extrapolated) infinity (AUC0-∞) in participants with mild or moderate HI is similar to that&#xD;
      of healthy control participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 29, 2021</start_date>
  <completion_date type="Anticipated">May 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 3, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Dosing to Infinity (AUC0-∞) of MK-8507</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 12, 24, 48, 96, 120, 168, 240, 336, and 504 hours postdose</time_frame>
    <description>The AUC0-∞ of MK-8507 will be determined in participants with mild or moderate HI and healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Dosing to Last Measurable Concentration (AUC0-last) of MK-8507</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 12, 24, 48, 96, 120, 168, 240, 336, and 504 hours postdose</time_frame>
    <description>The AUC0-last of MK-8507 will be determined in participants with mild or moderate HI and healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MK-8507</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 12, 24, 48, 96, 120, 168, 240, 336, and 504 hours postdose</time_frame>
    <description>The Cmax of MK-8507 will be determined in participants with mild or moderate HI and healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of MK-8507</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 12, 24, 48, 96, 120, 168, 240, 336, and 504 hours postdose</time_frame>
    <description>The Tmax of MK-8507 will be determined in participants with mild or moderate HI and healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Plasma Terminal Half-life (t½) of MK-8507</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 12, 24, 48, 96, 120, 168, 240, 336, and 504 hours postdose</time_frame>
    <description>The t½ of MK-8507 will be determined in participants with mild or moderate HI and healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Clearance from Plasma After Oral Administration (CL/F) of MK-8507</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 12, 24, 48, 96, 120, 168, 240, 336, and 504 hours postdose</time_frame>
    <description>The CL/F of MK-8507 will be determined in participants with mild or moderate HI and healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution during Terminal Phase (Vz/F) of MK-8507</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 12, 24, 48, 96, 120, 168, 240, 336, and 504 hours postdose</time_frame>
    <description>The Vz/F of MK-8507 will be determined in participants with mild or moderate HI and healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Adverse Event (AE)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Panel A: Mild HI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild HI receive a single oral dose of MK-8507 400 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B: Moderate HI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate HI receive a single oral dose of MK-8507 400 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C: Healthy Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy matched control participants receive a single oral dose of MK-8507 400 mg on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8507</intervention_name>
    <description>Four MK-8507 100 mg tablets (total dose 400 mg) taken by mouth.</description>
    <arm_group_label>Panel A: Mild HI</arm_group_label>
    <arm_group_label>Panel B: Moderate HI</arm_group_label>
    <arm_group_label>Panel C: Healthy Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Mild and Moderate HI (Panels A and B):&#xD;
&#xD;
          -  Has a diagnosis of chronic (&gt;6 months), stable HI with features of cirrhosis due to&#xD;
             any etiology (stability of hepatic disease should correspond to no acute episodes of&#xD;
             illness within the previous 2 months due to deterioration in hepatic function)&#xD;
&#xD;
        Healthy Controls (Panel C):&#xD;
&#xD;
          -  Is in good health&#xD;
&#xD;
        All Participants (Panels A to C):&#xD;
&#xD;
          -  Has a body mass index (BMI) ≥18.5 and ≤40 kg/m^2, inclusive&#xD;
&#xD;
          -  If male, uses contraception in accordance with local regulations&#xD;
&#xD;
          -  If female, is not pregnant or breastfeeding and one of the following applies: 1) is&#xD;
             not a woman of childbearing potential (WOCBP), or 2) is a WOCBP and is abstinent/uses&#xD;
             acceptable contraception, has a negative highly sensitive pregnancy test within 24&#xD;
             hours of receiving study intervention, and provides medical/menstrual/recent sexual&#xD;
             history for review by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Mild and Moderate HI (Panels A and B):&#xD;
&#xD;
          -  Has a history of any illness that, in the opinion of the investigator, might confound&#xD;
             the results of the study or poses an additional risk to the participant by their&#xD;
             participation in the study&#xD;
&#xD;
          -  Is not in sufficient health&#xD;
&#xD;
          -  Is institutionalized/mentally or legally incapacitated&#xD;
&#xD;
          -  Is positive for human immunodeficiency virus (HIV)-1 or HIV-2&#xD;
&#xD;
          -  Has received antiviral and/or immune modulating therapy for hepatitis B virus (HBV) or&#xD;
             hepatitis C virus (HCV) within 90 days prior to study start&#xD;
&#xD;
          -  Is taking medication for a chronic condition and has not been on a stable regimen for&#xD;
             ≥ 1 month&#xD;
&#xD;
        Healthy Controls (Panel C):&#xD;
&#xD;
          -  Has a history of clinically significant endocrine, gastrointestinal, cardiovascular,&#xD;
             hematological, hepatic, immunological, renal, respiratory, genitourinary, or major&#xD;
             neurological (including stroke and chronic seizures) abnormalities or diseases&#xD;
&#xD;
          -  Is mentally or legally incapacitated&#xD;
&#xD;
          -  Is positive for hepatitis B virus surface antigen (HBsAg), hepatitis C antibodies,&#xD;
             HIV-1, or HIV-2&#xD;
&#xD;
          -  Is unable to refrain from or anticipates the use of any medication, including&#xD;
             prescription and nonprescription drugs or herbal remedies beginning approximately 2&#xD;
             weeks (or 5 half-lives) prior to first dose of study drug&#xD;
&#xD;
        All Participants (Panel A to C):&#xD;
&#xD;
          -  Has a history of cancer (malignancy)&#xD;
&#xD;
          -  Has a history of significant multiple and/or severe allergies&#xD;
&#xD;
          -  Has known hypersensitivity to the active substance or any of the excipients of the&#xD;
             study drug&#xD;
&#xD;
          -  Has participated in another investigational study within 4 weeks (or 5 half-lives,&#xD;
             whichever is greater) prior to Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

